Autolus Therapeutics
AUTL
65 hedge funds and large institutions have $195M invested in Autolus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 14 closing their positions.
454% more call options, than puts
Call options by funds: $72K | Put options by funds: $13K
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
4% less capital invested
Capital invested by funds: $204M → $195M (-$9.03M)
3.41% less ownership
Funds ownership: 64.69% → 61.28% (-3.4%)
8% less funds holding
Funds holding: 71 → 65 (-6)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$3.32M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.48M |
| 3 |
BlackRock
New York
|
+$925K |
| 4 |
Millennium Management
New York
|
+$458K |
| 5 |
IAM
Innovis Asset Management
Chicago,
Illinois
|
+$247K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.44M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.35M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$1.19M |
| 4 |
AC
Armistice Capital
New York
|
-$1.08M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$950K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$19.8K | -10,407 | Closed |
|
77
Group One Trading
Chicago,
Illinois
| – | -$5.28K | -2,700 | Closed |
|
78
BNP Paribas Financial Markets
Paris,
France
| – | -$557 | -293 | Closed |
|
79
Citigroup
New York
| – | -$175 | -92 | Closed |
|
AUTL Hedge Fund Activity: Q1 2023 in Review
65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2023, worth a combined $195M — down 4.4% from $204M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AUTL and 9 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 20 added.
The largest buyer was TFG Asset Management, adding an estimated $3.32M. The largest seller was Alyeska Investment Group, cutting an estimated $2.44M.
- 65 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2023, down from 71 in Q4 2022.
- Funds reported $195M of Autolus Therapeutics stock for Q1 2023, down 4.4% quarter-over-quarter.
- 9 funds opened new Autolus Therapeutics positions in Q1 2023 and 14 closed out, a net change of -5 holders.
- The largest Autolus Therapeutics buyer in Q1 2023 was TFG Asset Management, an estimated $3.32M added.
- The largest Autolus Therapeutics seller in Q1 2023 was Alyeska Investment Group, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2023.